is a selective inhibitor of PDE5. The ef®cacy and safety of on-demand dosing of IC351 in men with erectile dysfunction was assessed in a multicenter, double-blind, placebocontrolled study. One hundred seventy-nine men (mean age: 56 y) were randomized to receive placebo or IC351 at doses of 2, 5, 10 or 25 mg, taken on demand over a 3-week period. The primary endpoints were change from baseline in responses to Questions 3 (Q3) and 4 (Q4) of the International Index of Erectile Function (IIEF). IC351 signi®cantly improved IIEF Q3 scores at all doses vs placebo (P 0.003). IC351 also signi®cantly improved IIEF Q4 scores in all but the 2 mg group (P 0.0003). No signi®cant changes in laboratory values, ECGs, or blood pressure were observed. The most common adverse events were headache and dyspepsia. The conclusion of this study was that on-demand IC351 at doses up to 25 mg was well tolerated and signi®cantly improved erectile function.
Introduction
Erectile dysfunction (ED) is a highly prevalent condition, 1,2 affecting an estimated 152 million men worldwide. 3 The disorder is associated with a range of behavioral risk factors, such as cigarette smoking and excessive alcohol consumption, as well as numerous age-related medical conditions, notably type 2 diabetes mellitus and cardiovascular disease. 2 As a result of these age-related co-morbidities, there is a higher prevalence of ED in older men. Between the ages of 40 and 70 y, for example, the incidence of complete ED triples from 5% to 15%, while the probability of moderate ED doubles from 17% to 34%. 2 Phosphodiesterase type 5 (PDE5) is a critical component of the nitric oxide (NO) Ð cGMP signaling pathway responsible for the modulation of smooth muscle tone in the penis. 4, 5 Inhibition of PDE5 magni®es the NO-mediated response to sexual stimulation, increasing intracellular concentrations of cGMP, thus facilitating the maintenance of penile erection. 5 Sildena®l, an inhibitor of PDE5, has been shown to be an effective treatment for ED. 6 ± 8 IC351 (Cialis TM ) is a potent and reversible inhibitor of PDE5 currently under investigation as a treatment for ED. In a previous dose-ranging study, a tablet-form research formulation of IC351 proved effective and well tolerated at daily doses up to 100 mg in men with mild-to-moderate ED. 9 The present study was undertaken to evaluate the effect of on-demand therapy with IC351 at lower doses (2 ± 25 mg) in men with a broad range of severity of ED. Ef®cacy was assessed on the basis of change from baseline in International Index of Erectile Function (IIEF) scores, 10 Sexual Encounter Pro®le (SEP) patient and partner diary data (Appendix A), and patient responses to a post-treatment global assessment question (GAQ) on the impact of treatment on their erections.
Methods
This multicenter, randomized, double-blind, placebo-controlled, parallel study was conducted in accordance with the Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines, and in conformity with the ethical principles of the Declaration of Helsinki. All patients and their partners provided written, informed consent.
Men between the ages of 21 and 72 y, inclusive, with a history of ED of at least 3 months' duration were eligible for study participation. All patients were required to be involved in a stable, monogamous relationship with a female partner. Exclusion criteria included ED caused by untreated endocrine disease; history of premature ejaculation, radical prostatectomy, immune disease, or diabetes mellitus; signi®cant or uncontrolled psychiatric disorders; clinically signi®cant hepatic, coronary artery, cardiovascular (within the last 6 months), or central nervous system (within the last 6 months) disease; prior unsuccessful use of a PDE5 inhibitor; and current treatment with nitrates, cancer chemotherapy agents, systemic corticosteroids, warfarin, or antiandrogens. Concomitant use of other therapies for ED was not allowed.
After screening for eligibility, patients entered a 21-day, treatment-free run-in period to determine baseline erectile function, during which at least four sexual attempts were required. If a patient had previously received pharmacological treatment for ED, he underwent a 7-day washout period prior to beginning the run-in period. Throughout the run-in period, patients and partners recorded their sexual encounters in Sexual Encounter Pro®le (SEP) diaries, consisting of a series of yesano questions regarding speci®c aspects of each sexual encounter (eg patient SEP Question 3:`Were you able to insert your penis into your partner's vagina?' and Patient SEP Question 4:`Did your erection last long enough for you to complete intercourse with ejaculation?'). At the end of the 21 days, baseline IIEF scores were obtained, SEP diary cards were reviewed, and patients were randomized to one of ®ve treatment arms: placebo or IC351 2 mg, 5 mg, 10 mg, or 25 mg. Patients were instructed to take a maximum of one dose daily as needed over a period of 21 days but not to exceed a total of 14 doses. Food and alcohol intake were not restricted. All patients agreed to attempt at least four sexual encounters during the treatment period.
Four clinic visits were scheduled: a screening visit (visit 1), at which histories were taken and SEP diary cards were distributed; a randomization visit (visit 2), at which study medication was distributed and baseline IIEF scores were obtained; an interim visit (visit 3) 7 days after treatment commenced; and a ®nal clinic visit (visit 4), at which a follow-up IIEF and the GAQ were administered. Seven to ten days after the treatment period (or study discontinuation), patients were contacted by telephone and asked about post-treatment adverse events and concomitant medications.
At all visits, vital signs (blood pressure, pulse, and weight) and clinical laboratory measurements (serum chemistry, hematology, and urinalysis) were assessed. Twelve-lead ECG was obtained at visits 1 and 4. SEP diary cards were reviewed at visits 2, 3, and 4. Information on adverse events (AEs) was elicited with nonleading questions.
The primary ef®cacy measure was change from baseline in scores on IIEF Question 3 (When you attempted sexual intercourse, how often were you able to penetrate [enter] your partner?) and Question 4 (During sexual intercourse, how often were you able to maintain your erection after you had penetrated [entered] your partner?). Additional ef®cacy measures included change from baseline in all domain scores of the IIEF, change from baseline in SEP reports, agreement between patients and partners in SEP reports, and patient response to the GAQ (Has the treatment you have been taking over the past study interval improved your erections?). AEs were classi®ed as any adverse changes from baseline that occurred during the study period.
Ef®cacy analyses were based on the intent-totreat (ITT) population, de®ned as all randomized patients. Ef®cacy was calculated as comparison to placebo after assessment of change from baseline at the end of the treatment period. Changes from baseline in IIEF Questions 3 and 4 were assessed by analysis of covariance (ANCOVA) with baseline scores as covariates. Changes from baseline in IIEF domain scores and SEP reports were compared by ANCOVA. Patient ± partner agreement in SEP reports was assessed using logistic regression, and between-group differences in the response to the post-treatment GAQ were assessed by Fisher's Exact test. Pairwise comparisons between all treatment groups were performed using the comparison of the least-square means or proportions, as appropriate. Safety analysis included all patients who took study drug. Results are presented as means AE s.e.m. or as percentages, as appropriate.
Results
A total of 179 men were randomized to receive treatment with placebo or IC351 2 mg, 5 mg, 10 mg, or 25 mg. The treatment groups were similar with regard to baseline demographics, clinical characteristics, and baseline IIEF scores ( Table 1 ). The overall mean age of patients was 56 y. Approximately two thirds of patients were current or former smokers, and two thirds reported current social drinking. Additionally, the patients randomized represented a broad range of ED severity as assessed by baseline IIEF score. 11 8.9% had mild ED, 37.6% had mild-tomoderate ED, 28.7% had moderate ED, and 24.8% had severe ED.
Of the 179 randomized men, 7 discontinued the study prior to completion: 2 were lost to follow-up, 2 withdrew due to AEs, 2 were withdrawn due to abnormal laboratory values prior to taking study drug, and 1 withdrew when his partner did.
IC351 enhances erectile function H Padma-Nathan et al *There were no signi®cant differences between groups for any parameters. IC351 enhances erectile function H Padma-Nathan et al IC351 improved the patients' ability to achieve (IIEF Question 3) and maintain (IIEF Question 4) erections. All doses of IC351 were associated with signi®cant improvements in mean IIEF Question 3 scores (P 0.003), while mean score declined in placebo-treated patients (Table 2; Figure 1 ). Mean scores on IIEF Question 4 increased signi®cantly compared with placebo in all but the 2-mg IC351 dose group (P 0.0003) (Table 2; Figure 2 ). Pairwise comparison of mean scores revealed no signi®cant differences in ef®cacy between the 5-, 10-and 25-mg doses of IC351 with regard to IIEF Question 3 or 4. Compared with placebo, all IC351 treatment groups showed signi®cant increases in mean scores in the Erectile Function (Figure 3 ), Orgasmic Function, Sexual Desire, and Overall Satisfaction domains of the IIEF (P 0.05) ( Table 2 ). All IC351 doses except 2 mg signi®cantly increased scores on the Intercourse Satisfaction domain (P 0.05) ( Table 2 ).
In addition, IC351 signi®cantly improved the percentage of successful intercourse attempts reported by patients compared with placebo, de®ned as the ability to achieve and maintain an erection suf®cient to complete intercourse with ejaculation (positive responses to both Question 3 and 4 of the SEP). Reports of successful intercourse attempts in the IC351 treatment groups increased from a pretreatment range of 28.2% ± 39.0% to an ontherapy range of 45.7% ± 70.2%. In the placebo group, the percentage of successful intercourse attempts increased from 23.0% pretreatment to 26.6% (Figure 4) . Patient results for SEP Question 3 (penetration ability) were mirrored by partner results, with post-treatment percentages of positive IC351 treatment was also associated with signi®-cant increases in the percentage of satisfying sexual experiences reported by patients (Patient SEP Question 6). These data were corroborated by the patients' partners (Partner SEP Question 4). Mean post-treatment percentages of overall satisfaction with sexual experience were up to 58.7% in patients and 63.7% in partners, compared with placebo values of 16.6% and 19.6%, respectively.
When asked about the impact of treatment on their erections, signi®cantly more IC351-treated patients indicated that treatment had improved their erections than did placebo-treated patients. IC351 treatment resulted in positive responses to the GAQ of 51.4% ± 80.6%, compared with 17.1% in placebo-treated patients ( Figure 5 ). IC351 treatment improved patient response to the GAQ regardless of baseline severity of ED (Table 3) . As with the IIEF parameters, there were no signi®cant differences between the 5, 10, and 25 mg groups with regard to ef®cacy as measured by SEP and GAQ.
IC351 was generally well tolerated. No deaths or treatment-related serious adverse events (SAEs) were reported during the study or follow-up period. 
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Two patients in the 10 mg dose group discontinued therapy due to AEs (one for headache and one for back pain, headache, nausea, and eyelid edema) that were considered treatment related by the investigators. Two patients, one each in the 2 and 25 mg dose groups, reported SAEs that required hospitalization (adenocarcinoma of the sigmoid colon and severe diverticulitis, respectively). Neither event was considered treatment related. Overall, 25.7% of IC351 patients and 8.6% of patients taking placebo reported at least one treatment-related AE. The incidence of AEs increased with increasing doses of the study drug, from 17.1% (2 mg) to 36.1% (25 mg). The most frequently reported treatment-related AEs were headache, dyspepsia, and backache (Table 4) 
Discussion
The recent introduction of an effective oral treatment for erectile dysfunction, sildena®l, 6 ± 8 has increased the number of patients seeking treatment for this prevalent medical disorder. IC351 is a potent and highly selective inhibitor of PDE5 being investigated for the treatment of ED. The present study investigated the therapeutic potential of IC351 in the dose range of 2 ± 25 mg in men with mild to severe ED. Men with organic, mixed, and psychogenic ED were eligible for inclusion in this study. Although men who had prior radical prostatectomy, erectile dysfunction from spinal cord injury, or diabetes mellitus were excluded from this phase II study, men with other organic etiologies were eligible for participation. The distribution of severity of ED in this study as measured by baseline IIEF Erectile Function domain score was comparable to that of the general population. 2 Several measures were used to assess erectile function in a natural setting, including the IIEF (a recall questionnaire), SEP diaries (event Although the 5, 10, and 25 mg dose groups did not differ statistically, there appeared to be a separation between the 5 mg dose group and the 10 and 25 mg dose groups. A therapeutic plateau was apparent between the 10 mg dose group and the 25 mg dose group in this population. IC351 treatment improved patients' overall assessment of treatment impact on erection (as measured by the GAQ), regardless of baseline severity of ED. This demonstrates the applicability of IC351 as effective treatment for a broad range of ED severity, with positive impact on erection assessment reported in up to 80% of patients with severe ED and up to 90% of patients with moderate ED.
In addition to patient data on success of sexual attempts and satisfaction with sexual experiences, data were also captured for all partners in SEP diaries. For SEP patient questions with a partner corollary, the post-treatment percentages of positive partner responses were very similar to those of the patients. For example, the percentages of positive responses to the question about penetration ability (SEP Question 3 for both patients and partners) differed by less than 2% between patients and their partners, suggesting the reliability of these diary data captured in a natural setting. Of interest, the percentage of positive partner responses to the question regarding satisfaction with the sexual experience was greater than that for patients in all treatment groups. These observations are unique and have not been reported previously.
IC351 was well tolerated in this study. Headache and dyspepsia were the most common AEs reported and were more common among patients receiving the 10 mg or 25 mg doses. Most AEs were reported as mild to moderate and attenuated with further treatment. Of interest, no abnormalities of color vision were reported, and¯ushing was reported in only one patient.
In this study, IC351 at doses up to 25 mg signi®cantly enhanced erectile function as assessed by the IIEF, SEP diaries, and a GAQ in a patient population with a wide range of severity of ED. IC351 was also well tolerated. Based on these data, IC351 may have the potential to become an important treatment option for ED.
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